Thursday Edition
Wednesday Edition

The 10^th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)

The following summarizes some of the highlights from Day 3 of MSToronto 2026.

New McDonald criteria increase diagnostic yield
First-line use of anti-CD20 agents: 2 studies
Do GLP-1 agonists have neuroprotective effects?
Obexelimab efficacy and safety
Ofatumumab vs. tocilizumab in MOGAD
Does EBV reactivation trigger MS relapses?
METEOROID trial of satralizumab in MOGAD
Clinical tip of the day
Read More

Friday Edition
Wednesday Edition

The 10^th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)

The following summarizes some of the highlights from Day 2 of MSToronto 2026.

DOT-MS discontinuation study
OPERETTA 2 results for ocrelizumab in POMS
PIRA in early- and late-onset MS
Impact of anti-CD20 on PIRA
Low rate of postpartum relapses with anti-CD20 therapy
Does EBV seronegativity preclude MS diagnosis?
Update on FENhance trials of fenebrutinib
Clinical tip of the day
Read More

MSToronto2026 – 10^th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026

Thursday, October 22. 16:30 – 18:30

Read More

Friday Edition
Thursday Edition

The 10^th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)

The following summarizes some of the highlights from Day 1 of MSToronto 2026.

MS risk with infectious mononucleosis
sNfL elevation postpartum
PRLs contribute to treatment failure
Update on frexalimab
Daratumumab effective in AQ4-IgG+ NMOSD
One-quarter of MS patients are untreated
Clinical tip of the day
Read More